REGENXBIO Inc. Other-than-temporary Impairment Loss, Debt Securities, Available-for-sale, Recognized in Earnings
REGENXBIO Inc. (RGNX) reported Other-than-temporary Impairment Loss, Debt Securities, Available-for-sale, Recognized in Earnings of $0 for the 9-month period ending 2019-09-30, per its 10-Q filed 2019-11-05.
Discontinued › Expense Statement › Operating Expenses
us-gaap:OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings · last filed 2019-11-05
- REGENXBIO Inc. other-than-temporary impairment loss, debt securities, available-for-sale, recognized in earnings for the quarter ending 2019-09-30 was $0.00.
- REGENXBIO Inc. other-than-temporary impairment loss, debt securities, available-for-sale, recognized in earnings for the quarter ending 2019-06-30 was $0.00.
- REGENXBIO Inc. other-than-temporary impairment loss, debt securities, available-for-sale, recognized in earnings for the quarter ending 2019-03-31 was $0.00.
| Period end | Other-than-temporary Impairment Loss, Debt Securities, Available-for-sale, Recognized in Earnings 3 month | Other-than-temporary Impairment Loss, Debt Securities, Available-for-sale, Recognized in Earnings 6 month | Other-than-temporary Impairment Loss, Debt Securities, Available-for-sale, Recognized in Earnings 9 month |
|---|---|---|---|
| 2019-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-05 | $0.00 derived: sum of 2 quarters · filed 2019-11-05 | $0.00 10-Q · filed 2019-11-05 |
| 2019-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-07 | $0.00 10-Q · filed 2019-08-07 | |
| 2019-03-31 | $0.00 10-Q · filed 2019-05-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B |